Predictive value of ENLIGHT-DP in patients with metastatic lung adenocarcinoma treated with immune checkpoint inhibitors and platinum chemotherapy directly from histopathology slides using inferred transcriptomics.

J Immunother Cancer · 2025 · PMC11749536 · PMID 39800380

Europe PMC DOI

hedged sentences

0.0660

closest p · 1.3× alpha

0.0660

boldest claim

The sentences

borderline significantp=0.066so close (0.05 < p ≤ 0.1)

EMS is the only marker significantly correlated with first-line ICI PFS (HR: 0.45, 95% CI: 0.2 to 0.99 p=0.048) and borderline significant with OS (HR: 0.31, 95% CI: 0.09 to 1.08 p=0.066).

also in 11,409 other papers

showed a trendno p-value reported

ENLIGHT-DP was able to significantly predict PFS for this cohort but only showed a trend in predicting OS.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.